CCM
PKBO

CAAS Capital Management’s Peak Bio, Inc. Common Stock PKBO Stock Holding History

CAAS Capital Management’s Portfolio PKBO Stock Details PKBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,152
Closed -$251K – 1034
2022
Q3 		$251K Hold
25,152
– – 0.01% 609
2022
Q2 		$248K Buy
+25,152
New +$248K 0.01% 634

Other funds holding PKBO

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CAAS Capital Management's PKBO Position: Q4 2022 in Review

CAAS Capital Management sold out of Peak Bio, Inc. Common Stock (PKBO) in Q4 2022, closing a stake of 25,152 shares — an estimated $251K sold.

CAAS Capital Management first reported a position in PKBO in Q2 2022 and held it in 2 quarters. The position peaked at $251K in Q3 2022. 9 funds tracked by Wall St. Rank hold PKBO as of Q4 2022.

  • CAAS Capital Management reported no remaining Peak Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 25,152 Peak Bio, Inc. Common Stock shares in Q4 2022, an estimated $251K.
  • CAAS Capital Management first reported a position in Peak Bio, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • CAAS Capital Management's Peak Bio, Inc. Common Stock position peaked at $251K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Peak Bio, Inc. Common Stock as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.